Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Article Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostSubmitted by Chris Markoch. Article Published: 2/5/2026. 
Article Highlights - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average (DJIA) the day after reporting a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study of its lead GLP-1 candidate. Do you own the worst stock of 2026? [Name + Ticker]
He issued warnings for RNG before it crashed 89%, BYND before it crashed 90%, TDOC before it crashed 84%, and FVRR before it crashed 86%. Now, he's stepping forward to name the popular stock that could go down as one of the worst-performing tickers of the year. It could be the most dangerous stock of 2026. Click here for its name and ticker, 100% free. PFE stock closed up 4% on Feb. 4 as analysts and investors had a chance to digest the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and its accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. One forecast shows the global GLP-1 market growing from $62.2 billion in 2025 to $157 billion by 2035. That implies a compound annual growth rate (CAGR) of about 9.7%, explaining why billions of dollars are flowing into the industry as companies jockey for market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. The company reported results from its Phase 2b VESPER-3 study: the trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom attributed the stock's gain to the positive clinical trial results. That may be true, but investors should view that as a near-term catalyst rather than the whole story. While Pfizer's GLP-1 program shows promise, it will take time for sales to meaningfully move the company's financials. The GLP-1 market is also expanding rapidly, and large competitors—like Eli Lilly & Co. (NYSE: LLY)—aren't ceding leadership in obesity drugs anytime soon. However, there are other reasons to be bullish on PFE—most notably, its oncology portfolio. Business Research Insights values the global oncology drugs market at approximately $264.92 billion in 2026, projected to climb to $648.08 billion by 2035, reflecting a CAGR of around 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its product portfolio—about as many opportunities to capture market share. The company's pipeline was strengthened substantially by its acquisition of Seagen in 2023. Pfizer's portfolio now includes a mix of late-stage programs, such as Vepdegestrant, a next-generation targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor, both being evaluated to treat ER+/HER2- metastatic breast cancer in later-stage trials. Other late-stage candidates include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) targeting metastatic non-small cell lung cancer, leveraging Pfizer's Seagen-acquired ADC expertise.
- Sasanlimab, under investigation for bladder cancer; and a bispecific PD-1xVEGF agent (PF-4404) being developed in combination with Padcev to treat urothelial cancer—programs positioned for potential blockbuster outcomes amid oncology growth.
As noted, Pfizer could bring multiple new drugs to market over the next five to 10 years. That opportunity is amplified by the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships—Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics—and with tools like OncoScout that can speed target identification substantially. Internally, platforms such as "Charlie" are used for data mining, predictions and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing workflows. These AI efforts were critical in the rapid development of Paxlovid and support 2026 catalysts across oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 from efficiency gains. Industry-wide, AI is projected to boost productivity by roughly 35% to 45% by improving preclinical decisions and trial design, making it a core competitive advantage rather than optional hype. Pfizer has positioned itself near the forefront of AI adoption in pharma, which should be a meaningful tailwind for investors over the medium and long term.
| 
